Skip to main content
SpringerLink
Log in

Botulinumtoxin für Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007

Ein interdisziplinärer deutscher Konsensus

Botulin toxin for children with cerebral palsy: 10-point table, 2007

An interdisciplinary consensus within Germany

  • Konsensuspapiere
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ackman JD, Russman BS, Thomas SS et al. (2005) Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 47: 620–627

    Article  PubMed  Google Scholar 

  2. Ade-Hall RA, Moore AP (2000) Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev 2: CD001408

    PubMed  Google Scholar 

  3. Allington NJ, Leroy N, Doneux C (2002) Ankle joint range of motion measurements in spastic cerebral palsy children: intraobserver and interobserver reliability and reproducibility of goniometry and visual estimation. J Pediatr Orthop B 11: 236–239

    Article  PubMed  Google Scholar 

  4. Anonymos (2000) Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 42: 816–824

    PubMed  Google Scholar 

  5. Anonymos (2007) The definition and classification of cerebral palsy. Dev Med Child Neurol 49: 1–44

    Google Scholar 

  6. Aoki KR (2001) A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39: 1815–1820

    Article  PubMed  CAS  Google Scholar 

  7. Ashwal S, Russman BS, Blasco PA et al. (2004) Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 62: 851–863

    PubMed  CAS  Google Scholar 

  8. Autti-Ramo I, Larsen A, Taimo A et al. (2001) Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol [Suppl 5] 8: 136–144

    Google Scholar 

  9. Autti-Ramo I, Anttila H, Makela M (2007) Are current practices in the treatment of children with cerebral palsy research-based? Dev Med Child Neurol 49: 155–156

    PubMed  Google Scholar 

  10. Baker R, Jasinski M, Maciag-Tymecka I et al. (2002) Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 44: 666–675

    Article  PubMed  CAS  Google Scholar 

  11. Bakheit AM, Bower E, Cosgrove A et al. (2001) Opinion statement on the minimal acceptable standards of healthcare in cerebral palsy. Disabil Rehabil 23: 578–582

    Article  PubMed  CAS  Google Scholar 

  12. Bakheit AM, Severa S, Cosgrove A et al. (2001) Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43: 234–238

    Article  PubMed  CAS  Google Scholar 

  13. Balkrishnan R, Camacho FT, Smith BP et al. (2002) Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy. J South Orthop Assoc 11: 71–79

    PubMed  Google Scholar 

  14. Balkrishnan R, Naughton M, Smith BP et al. (2002) Parent caregiver-related predictors of health care service utilization by children with cerebral palsy enrolled in Medicaid. J Pediatr Health Care 16: 73–78

    PubMed  Google Scholar 

  15. Balkrishnan R, Manuel JC, Smith BP et al. (2004) Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy. J Surg Orthop Adv 13: 76–80

    PubMed  Google Scholar 

  16. Barbano RL (2001) Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 24: 1567–1568

    Article  PubMed  CAS  Google Scholar 

  17. Barwood S, Baillieu C, Boyd R et al. (2000) Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 42: 116–121

    Article  PubMed  CAS  Google Scholar 

  18. Bax M, Goldstein M, Rosenbaum P et al. (2005) Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 47: 571–576

    Article  PubMed  Google Scholar 

  19. Beckung E, Hagberg G (2002) Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 44: 309–316

    Article  PubMed  Google Scholar 

  20. Berweck S, Feldkamp A, Francke A et al. (2002) Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropediatrics 33: 221–223

    Article  PubMed  CAS  Google Scholar 

  21. Berweck S, Heinen F (2006) Therapie der Cerebralparese mit Botulinumtoxin – Grundlagen, Praxis, Atlas, Blue Book, 2nd edn. Child & Brain GmbH, Bonn Berlin

  22. Berweck S, Schroeder AS, Fietzek UM et al. (2004) Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 363: 249–250

    Article  PubMed  Google Scholar 

  23. Berweck S, Schroeder AS, Lee SH et al. (2007) Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands. Dev Med Child Neurol 49: 62–64

    Article  PubMed  Google Scholar 

  24. Bjornson KF, McLaughlin JF (2001) The measurement of health-related quality of life (HRQL) in children with cerebral palsy. Eur J Neurol [Suppl 5] 8: 183–193

    Google Scholar 

  25. Blasi J, Chapman E, Link E et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP 25. Nature 365: 160–163

    Article  PubMed  ADS  CAS  Google Scholar 

  26. Bower E, McLellan DL (1994) Evaluating therapy in cerebral palsy. Child Care Health Dev 20: 409–419

    Article  PubMed  CAS  Google Scholar 

  27. Boyd RN, Graham HK (1999) Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol [Suppl 4] 6: 23–35

  28. Boyd RN, Dobson F, Parrott J et al. (2001) The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol [Suppl 5] 8: 109–119

    Google Scholar 

  29. Bucheler R, Schwab M, Morike K et al. (2002) Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 324: 1311–1312

    Article  PubMed  Google Scholar 

  30. Cans C, Dolk H, Platt M et al. (2007) Recommendations from the SCPE collaboration group for defining and classifying cerebral palsy. Dev Med Child Neurol 109: 35–38

    Google Scholar 

  31. Carr LJ, Cosgrove AP, Gringras P et al. (1998) Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party. Arch Dis Child 79: 271–273

    PubMed  CAS  Google Scholar 

  32. Chambers HG (2001) Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. Eur J Neurol [Suppl 5] 8: 59–74

    Google Scholar 

  33. Chin TY, Nattrass GR, Selber P et al. (2005) Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 25: 286–291

    Article  PubMed  Google Scholar 

  34. Conroy S, Choonara I, Impicciatore P et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320: 79–82

    Article  PubMed  CAS  Google Scholar 

  35. Corry IS, Cosgrove AP, Walsh EG et al. (1997) Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 39: 185–193

    Article  PubMed  CAS  Google Scholar 

  36. Corry IS, Cosgrove AP, Duffy CM et al. (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 18: 304–311

    Article  PubMed  CAS  Google Scholar 

  37. Cusick A, McIntyre S, Novak I et al. (2006) A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil 9: 149–157

    Article  PubMed  CAS  Google Scholar 

  38. Damiano DL, Quinlivan JM, Owen BF et al. (2002) What does the Ashworth scale really measure and are instrumented measures more valid and precise? Dev Med Child Neurol 44: 112–118

    Article  PubMed  Google Scholar 

  39. Desloovere K, Molenaers G, Jonkers I et al. (2001) A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol [Suppl 5] 8: 75–87

    Google Scholar 

  40. Dong M, Yeh F, Tepp WH et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592–596

    Article  PubMed  ADS  CAS  Google Scholar 

  41. Dressler D, Rothwell JC (2000) Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43: 13–16

    Article  PubMed  CAS  Google Scholar 

  42. Eames NW, Baker R, Hill N et al. (1999) The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 41: 226–232

    Article  PubMed  CAS  Google Scholar 

  43. Eliasson AC, Krumlinde-Sundholm L, Shaw K et al. (2005) Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model. Dev Med Child Neurol 47: 266–275

    Article  PubMed  Google Scholar 

  44. Eliasson AC, Rösblad B, Beckung E et al. (2005) Development and reliability of a system to classify hand function in children with cerebral palsy: Manual Ability Classification System (MACS). AACPDM, Orlando, FA

    Google Scholar 

  45. Eliasson AC, Krumlinde-Sundholm L, Rosblad B et al. (2006) The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 48: 549–554

    Article  PubMed  Google Scholar 

  46. Fehlings D, Rang M, Glazier J et al. (2000) An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 137: 331–337

    Article  PubMed  CAS  Google Scholar 

  47. Feldman AB, Haley SM, Coryell J (1990) Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 70: 602–610

    PubMed  CAS  Google Scholar 

  48. Flett PJ (2003) Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 39: 6–14

    Article  PubMed  CAS  Google Scholar 

  49. Flett PJ, Stern LM, Waddy H et al. (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35: 71–77

    Article  PubMed  CAS  Google Scholar 

  50. Foran JR, Steinman S, Barash I et al. (2005) Structural and mechanical alterations in spastic skeletal muscle. Dev Med Child Neurol 47: 713–717

    Article  PubMed  Google Scholar 

  51. Fosang AL, Galea MP, McCoy AT et al. (2003) Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol 45: 664–670

    Article  PubMed  Google Scholar 

  52. Frampton A, Browne GJ, Lam LT et al. (2003) Nurse administered relative analgesia using high concentration nitrous oxide to facilitate minor procedures in children in an emergency department. Emerg Med J 20: 410–413

    Article  PubMed  CAS  Google Scholar 

  53. Gormley ME Jr, Krach LE, Piccini L (2001) Spasticity management in the child with spastic quadriplegia. Eur J Neurol [Suppl 5] 8: 127–135

    Google Scholar 

  54. Gracies JM (2004) Physiological effects of botulinum toxin in spasticity. Mov Disord [Suppl 8] 19: S120–128

  55. Graham HK, Selber P (2003) Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg Br 85: 157–166

    Article  PubMed  Google Scholar 

  56. Graham HK, Aoki KR, Autti-Ramo et al. (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67–79

    Article  PubMed  CAS  Google Scholar 

  57. Hagglund G, Andersson S, Duppe H et al. (2005) Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 14: 268–272

    Google Scholar 

  58. Heinen F, Molenaers G, Fairhurst C et al. (2006) European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 10: 215–225

    Article  PubMed  Google Scholar 

  59. Heinen F, Schroeder AS, Fietzek U et al. (2006) When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. Mov Disord 21: 2029–2030

    Article  PubMed  Google Scholar 

  60. Herrmann J, Geth K, Mall V et al. (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732–735

    Article  PubMed  CAS  Google Scholar 

  61. Himmelmann K, Hagberg G, Beckung E et al. (2005) IX. Prevalence and origin in the birth-year period 1995–1998. Acta Paediatr 94: 287–294

    Article  PubMed  CAS  Google Scholar 

  62. Hoare BJ, Imms C (2004) Upper-limb injections of botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. Am J Occup Ther 58: 389–397

    Article  PubMed  Google Scholar 

  63. Hoon AH, Johnston MV (2002) Cerebral palsy. In: Asbury AK, McKhann GM, McDonald WI et al. (eds) Diseases of the nervous system. Clinical neuroscience and therapeutic principles. Cambridge University Press, Cambridge, pp 568–580

  64. Houltram J, Noble I, Boyd RN et al.(2001) Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol [Suppl 5] 8: 194–202

    Google Scholar 

  65. Ijzerman MJ, Nene AV (2002) Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil 83: 1777–1782

    Article  PubMed  Google Scholar 

  66. Jankovic J (2001) Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 24: 1568–1570

    Article  PubMed  CAS  Google Scholar 

  67. Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186–1188

    PubMed  CAS  Google Scholar 

  68. Jarvis S, Glinianaia SV, Torrioli MG et al. (2003) Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 362: 1106–1111

    Article  PubMed  Google Scholar 

  69. Jefferson RJ (2004) Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 46: 491–499

    Article  PubMed  Google Scholar 

  70. Kanagasundaram SA, Lane LJ, Cavalletto BP et al. (2001) Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures. Arch Dis Child 84: 492–495

    Article  PubMed  CAS  Google Scholar 

  71. Kay RM, Rethlefsen SA, Fern-Buneo A et al. (2004) Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am 86-A: 2377–2384

  72. Keefer DJ, Tseh W, Caputo JL et al. (2004) Comparison of direct and indirect measures of walking energy expenditure in children with hemiplegic cerebral palsy. Dev Med Child Neurol 46: 320–324

    Article  PubMed  Google Scholar 

  73. Kennedy RM, Luhmann JD, Luhmann SJ (2004) Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children. Paediatr Drugs 6: 11–31

    Article  PubMed  Google Scholar 

  74. Ketelaar M, Vermeer A, Helders PJ (1998) Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clin Rehabil 12: 369–380

    Article  PubMed  CAS  Google Scholar 

  75. King S, Teplicky R, King G et al. (2004) Family-centered service for children with cerebral palsy and their families: a review of the literature. Semin Pediatr Neurol 11: 78–86

    Article  PubMed  Google Scholar 

  76. Kinnett D (2004) Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 83: S59–64

    Article  PubMed  Google Scholar 

  77. Koman LA, Mooney JF, Smith BP et al. (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 20: 108–115

    Article  PubMed  CAS  Google Scholar 

  78. Koman LA, Brashear A, Rosenfeld S et al. (2001) Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108: 1062–1071

    Article  PubMed  CAS  Google Scholar 

  79. Koman LA, Paterson SB, Balkrishnan R (2003) Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. PaediatrDrugs 5: 11–23

    Google Scholar 

  80. Koman LA, Smith BP, Shilt JS (2004) Cerebral palsy. Lancet 363: 1619–1631

    Article  PubMed  Google Scholar 

  81. Krageloh-Mann I (2004) Imaging of early brain injury and cortical plasticity. Exp Neurol [Suppl 1] 190: S84–90

  82. Krageloh-Mann I (2005) Cerebral palsy: towards developmental neuroscience. Dev Med Child Neurol 47: 435

    Article  PubMed  Google Scholar 

  83. Krageloh-Mann I, Horber V (2007) The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: a systematic review. Dev Med Child Neurol 49: 144–151

    PubMed  Google Scholar 

  84. Krageloh-Mann I, Hagberg G, Meisner C et al. (1994) Bilateral spastic cerebral palsy – a comparative study between southwest Germany and western Sweden. II: Epidemiology. Dev Med Child Neurol 36: 473–483

    Article  PubMed  CAS  Google Scholar 

  85. Lannin N, Scheinberg A, Clark K (2006) AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 48: 533–539

    Article  PubMed  Google Scholar 

  86. Leach J (1997) Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve Suppl 6: S194–207

    Article  PubMed  CAS  Google Scholar 

  87. Linder-Lucht M, Kirschner J, Herrmann J et al. (2006) Why do children with cerebral palsy discontinue therapy with botulinum toxin A? Dev Med Child Neurol 48: 319–320

    Article  PubMed  Google Scholar 

  88. Liptak GS, Accardo PJ (2004) Health and social outcomes of children with cerebral palsy. J Pediatr 145: S36–41

    Article  PubMed  Google Scholar 

  89. Love SC, Valentine JP, Blair EM et al. (2001) The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia. An randomized controlled trial. Eur J Neurol [Suppl 5] 8: 50–58

    Google Scholar 

  90. Lowe K, Novak I, Cusick A (2006) Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 48: 170–175

    Article  PubMed  Google Scholar 

  91. Maathuis KG, Van der Schans CP, Van Iperen A et al. (2005) Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing Scale. J Pediatr Orthop 25: 268–272

    Article  PubMed  Google Scholar 

  92. Mackey AH, Lobb GL, Walt SE et al. (2003) Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol 45: 4–11

    Article  PubMed  Google Scholar 

  93. Mahrhold S, Rummel A, Bigalke H et al. (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Letters 580: 2011–2014

    Article  PubMed  CAS  Google Scholar 

  94. Majnemer A, Mazer B (2004) New directions in the outcome evaluation of children with cerebral palsy. Semin Pediatr Neurol 11: 11–17

    Article  PubMed  Google Scholar 

  95. Mall V, Heinen F, Kirschner J et al. (2000) Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol 15: 214–217

    PubMed  CAS  Google Scholar 

  96. Mall V, Kirschner J, Linder M et al. (2003) Botulinum toxin A in children with cerebral palsy: evaluation of therapy with Pediatric Evaluation of Disability Inventory (PEDI). Pediatr Neurol 1: 29–34

    Article  CAS  Google Scholar 

  97. Mall V, Heinen F, Siebel A et al. (2006) Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 48: 10–13

    Article  PubMed  Google Scholar 

  98. Maloney FP (1993) Goal attainment scaling. Phys Ther 73: 123

    PubMed  CAS  Google Scholar 

  99. Maloney FP, Mirrett P, Brooks C et al. (1978) Use of the Goal Attainment Scale in the treatment and ongoing evaluation of neurologically handicapped children. Am J Occup Ther 32: 505–510

    PubMed  CAS  Google Scholar 

  100. McCarthy ML, Silberstein CE, Atkins EA et al. (2002) Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. Dev Med Child Neurol 44: 468–476

    Article  PubMed  MathSciNet  Google Scholar 

  101. McDowell BC, Hewitt V, Nurse A et al. (2000) The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. Gait Posture 12: 114–121

    Article  PubMed  CAS  Google Scholar 

  102. Mohamed K, Moore AP, Rosenbloom L (2001) Adverse events following repeated injections with botulinum toxin A in children with spasticity. Dev Med Child Neurol 43: 791–792

    Article  PubMed  CAS  Google Scholar 

  103. Molenaers G, Eyssen M, Desloovere K et al. (1999) A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol [Suppl 4] 6: 59–62

  104. Molenaers G, Desloovere K, Fabry G et al. (2006) The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 88: 161–170

    Article  PubMed  Google Scholar 

  105. Moore AP, Ade-Hall RA, McDowell M et al. (2001) Children with cerebral palsy tolerate repeated botulinum toxin injection sessions without general anaestethic. Mov Disord 16: 381

    Article  Google Scholar 

  106. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20: 981–990

    Article  PubMed  CAS  Google Scholar 

  107. O’Donnell M, Darrah J, Adams R et al. (2004) AACPDM methodology to develop systematic reviews of treatment interventions. http://wwwaacpdmorg/index?service=page/treatmentOutcomes (accessed march 2007)

  108. Palisano RJ (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73: 651–658

    PubMed  CAS  Google Scholar 

  109. Palisano R, Rosenbaum PL, Walter S et al. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39: 214–223

    Article  PubMed  CAS  Google Scholar 

  110. Palisano RJ, Hanna SE, Rosenbaum PL et al. (2000) Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 80: 974–985

    PubMed  CAS  Google Scholar 

  111. Palisano RJ, Cameron D, Rosenbaum PL et al. (2006) Stability of the gross motor function classification system. Dev Med Child Neurol 48: 424–428

    Article  PubMed  Google Scholar 

  112. Petruch U, Weber PM, Krageloh-Mann I, SCPE obot (2004) The reference and training manual of the SCPE (Surveillance of Cerebral Palsy in Europe). Neuropediatrics: 63

  113. Platt MJ, Cans C, Johnson A et al. (2007) Trends in cerebral palsy among infants of very low birth weight (<1500 g) or born prematurely (<32 weeks) in 16 European centres: a database study. Lancet 369: 43–50

    Article  PubMed  Google Scholar 

  114. Polak F, Morton R, Ward C et al. (2002) Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 44: 551–555

    Article  PubMed  Google Scholar 

  115. Radensky PW, Archer JW, Dournaux SF et al. (2001) The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 15: 57–68

    Article  PubMed  CAS  Google Scholar 

  116. Read HS, Hazlewood ME, Hillman SJ et al. (2003) Edinburgh visual gait score for use in cerebral palsy. J Pediatr Orthop 23: 296–301

    Article  PubMed  Google Scholar 

  117. Reddihough DS, King JA, Coleman GJ et al. (2002) Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44: 820–827

    Article  PubMed  Google Scholar 

  118. Rodda J, Graham HK (2001) Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol [Suppl 5] 8: 98–108

    Google Scholar 

  119. Rosales RL, Bigalke H, Dressler D (2006) Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol [Suppl 1] 13: 2–10

    Google Scholar 

  120. Rose J, Gamble JG, Lee J et al. (1991) The energy expenditure index: a method to quantitate and compare walking energy expenditure for children and adolescents. J Pediatr Orthop 11: 571–578

    PubMed  CAS  Google Scholar 

  121. Rosenbaum P, Stewart D (2004) The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. Semin Pediatr Neurol 11: 5–10

    Article  PubMed  Google Scholar 

  122. Sanger TD (2003) Pathophysiology of pediatric movement disorders. J Child Neurol [Suppl 1] 18: S9–24

    Google Scholar 

  123. Sanger TD, Delgado MR, Gaebler-Spira D et al. (2003) Classification and definition of disorders causing hypertonia in childhood. Pediatrics 111: e89–97

    Article  PubMed  Google Scholar 

  124. Satila H, Kotamaki A, Koivikko M et al. (2006) Low- and high-dose botulinum toxin A treatment: a retrospective analysis. Pediatr Neurol 34: 285–290

    Article  PubMed  Google Scholar 

  125. Schiavo G, Benfenati F, Poulain B et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]. Nature 359: 832–835

    Article  PubMed  ADS  CAS  Google Scholar 

  126. Schmid MF, Robinson JP, DasGupta BR (1993) Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. Nature 364: 827–830

    Article  PubMed  ADS  CAS  Google Scholar 

  127. Schneider JW, Gurucharri LM, Gutierrez AL et al. (2001) Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol 43: 601–608

    Article  PubMed  CAS  Google Scholar 

  128. Schroeder AS, Berweck S, Lee SH et al. (2006) Botulinum toxin treatment of children with cerebral palsy – a short review of different injection techniques. Neurotox Res 9: 189–196

    Article  PubMed  CAS  Google Scholar 

  129. Schwerin A, Berweck S, Fietzek UM et al. (2004) Botulinum toxin B treatment in children with spastic movement disorders: a pilot study. Pediatr Neurol 31: 109–113

    Article  PubMed  Google Scholar 

  130. SCPE (2002) Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 44: 633–640

    Article  PubMed  Google Scholar 

  131. Sheean GL (2001) Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 14: 771–776

    Article  PubMed  CAS  Google Scholar 

  132. Speth LA, Leffers P, Janssen-Potten YJ et al. (2005) Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 47: 468–473

    Article  PubMed  CAS  Google Scholar 

  133. Stanley FJ, Blair EM, Alberman E (2000) Cerebral palsies: epidemiology and causal pathways. MacKeith Press, London

    Google Scholar 

  134. Steinlin M, Heinen F (2003) Stellungnahme der Gesellschaft für Neuropädiatrie. Therapeutischer Wert von Botulinumtoxin bei der Behandlung von Bewegungsstörungen mit Spastizität im Kindesalter. Neuropädiatr Klin Prax 4: 171

    Google Scholar 

  135. Sutherland DH, Kaufman KR, Wyatt MP et al. (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10: 1–9

    Article  PubMed  CAS  Google Scholar 

  136. Tilton AH (2003) Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol [Suppl 1] 18: S50–66

  137. Tilton AH, Maria BL (2001) Consensus statement on pharmacotherapy for spasticity. J Child Neurol 16: 66–67

    Article  PubMed  ADS  CAS  Google Scholar 

  138. Ubhi T, Bhakta BB, Ives HL et al. (2000) Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy [In Process Citation]. Arch Dis Child 83: 481–487

    Article  PubMed  CAS  Google Scholar 

  139. Valtorta F, Arslan G (1993) The pharmacology of botulinum toxin. Pharmacol Res 27: 33–44

    Article  PubMed  CAS  Google Scholar 

  140. Wallen MA, O’Flaherty S J, Waugh MC (2004) Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 85: 192–200

    Article  PubMed  Google Scholar 

  141. Wasiak J, Hoare B, Wallen M (2004) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004: CD003469

    Google Scholar 

  142. Wenger DR, Rang M (1993) The art and practice of children’s orthopedics. Raven Press, New York

  143. Westhoff B, Seller K, Wild A et al. (2003) Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle. Dev Med Child Neurol 45: 829–832

    Article  PubMed  Google Scholar 

  144. WHO (2003) Strategy for child and adolescent health and development. Executive Board of the WHO, 111th Session, New York

  145. Wissel J, Muller J, Dressnandt J et al. (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20: 44–49

    Article  PubMed  CAS  Google Scholar 

  146. Wood E, Rosenbaum P (2000) The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol 42: 292–296

    Article  PubMed  CAS  Google Scholar 

  147. Zurcher AW, Molenaers G, Desloovere K et al. (2001) Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy. Acta Orthop Belg 67: 475–480

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Florian Heinen, München, initiierte sowohl das europäische als auch das deutsche Treffen an der LMU München. Die Organisation dieser Treffen wurde durch die Fa. Allergan unterstützt. Die Autoren haben für Vortragstätigkeiten zum Themenbereich Zerebralparesen von den Firmen Allergan Inc., Ipsen, Ltd., und Merz Pharmaceuticals GmbH Honorare erhalten.

Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Consortia

Gesellschaft für Neuropädiatrie (GNP)

Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP)

Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ)

Arbeitskreis Infantile Cerebralparesen der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC)

Deutsche Gesellschaft für Neurologische Rehabilitation (DGNR)

Deutschsprachige Vereinigung für Kinderorthopädie

Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie (AK-BoNT der DGN)

Additional information

Die europäische Vorlage wurde publiziert in: Eur J Paediatr Neurol (2006) 10: 215–225. Mit freundlicher Genehmigung von Elsevier, Deutschland

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gesellschaft für Neuropädiatrie (GNP)., Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP)., Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ). et al. Botulinumtoxin für Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007. Monatsschr Kinderheilkd 155, 537–543 (2007). https://doi.org/10.1007/s00112-007-1516-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-007-1516-7

Search

Navigation